10-K: FY2024 Annual Report
Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Lexaria Bioscience Announces That It Has Received Partial 12-Week Body Weight Results From The Recently Completed Animal Study WEIGHT-A24-1